Last reviewed · How we verify
Continued Paroxetine CR
Continued Paroxetine CR is a Selective serotonin reuptake inhibitor (SSRI) Small molecule drug developed by Massachusetts General Hospital. It is currently FDA-approved for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
Paroxetine CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft.
Paroxetine CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | Continued Paroxetine CR |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Paroxetine selectively inhibits the reuptake of serotonin at the presynaptic neuronal membrane, leading to increased serotonin concentration in the synaptic space. This enhanced serotonergic neurotransmission is thought to improve mood and reduce anxiety symptoms. The CR (controlled-release) formulation provides sustained drug delivery over 24 hours, improving tolerability and compliance.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Panic disorder
- Social anxiety disorder
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Somnolence
- Sexual dysfunction
- Diarrhea
- Sweating
- Tremor
Key clinical trials
- Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment (PHASE3)
- Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continued Paroxetine CR CI brief — competitive landscape report
- Continued Paroxetine CR updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI
Frequently asked questions about Continued Paroxetine CR
What is Continued Paroxetine CR?
How does Continued Paroxetine CR work?
What is Continued Paroxetine CR used for?
Who makes Continued Paroxetine CR?
What drug class is Continued Paroxetine CR in?
What development phase is Continued Paroxetine CR in?
What are the side effects of Continued Paroxetine CR?
What does Continued Paroxetine CR target?
Related
- Drug class: All Selective serotonin reuptake inhibitor (SSRI) drugs
- Target: All drugs targeting Serotonin transporter (SERT)
- Manufacturer: Massachusetts General Hospital — full pipeline
- Therapeutic area: All drugs in Psychiatry / Mental Health
- Indication: Drugs for Major depressive disorder
- Indication: Drugs for Generalized anxiety disorder
- Indication: Drugs for Panic disorder
- Compare: Continued Paroxetine CR vs similar drugs
- Pricing: Continued Paroxetine CR cost, discount & access